August 10, 2015 — IBA (Ion Beam Applications S.A.) announced the completion of the divestiture of IBA Molecular North America Inc. (IBAM NA) to Illinois Health and Science (IHS), a non-profit healthcare system.
IBAM NA is the U.S. subsidiary of IBA Molecular (IBAM), a joint-venture owned by IBA S.A. and SK Capital Partners. The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities.
The proceeds will be used to repay outstanding debt at IBAM and to make a distribution to IBAM’s shareholders (IBA S.A. owns 40 percent of IBAM). The transaction is not expected to have a significant impact on IBA’s 2015 profits and loss (P&L) but will generate cash proceeds of approximately EUR 10 million for IBA during the third quarter of 2015.
For more information: www.ibamolecular.com
October 16, 2026 
